Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GNT002
MIFTS: 57

Giant Cell Glioblastoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Giant Cell Glioblastoma

About this section

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 58 54 6 15 71
Monstrocellular Sarcoma 12 71

Characteristics:

Orphanet epidemiological data:

58
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 44 D005909
NCIt 50 C4325
SNOMED-CT 67 44529004
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334588
Orphanet 58 ORPHA251579
UMLS 71 C0334588 C0334593
Sources

Summaries for Giant Cell Glioblastoma

About this section
Disease Ontology : 12 A glioblastoma that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to pleomorphic xanthoastrocytoma and glioma susceptibility 1, and has symptoms including seizures and headache. An important gene associated with Giant Cell Glioblastoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Dasatinib and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Sources

Related Diseases for Giant Cell Glioblastoma

About this section

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 pleomorphic xanthoastrocytoma 30.9 TP53 MGMT IDH1 H3-3A BRAF
2 glioma susceptibility 1 30.7 TP53 LZTR1 IDH1 H3-3A
3 gemistocytic astrocytoma 30.5 TP53 PTEN IDH1
4 glioblastoma 30.5 TP53 PTEN POLE PIK3R1 PIK3CA MSH2
5 malignant astrocytoma 30.5 TP53 PTEN MGMT IDH1 H3-3A EGFR
6 ganglioglioma 30.4 TP53 H3-3A BRAF
7 papilloma 30.4 TP53 PTEN FGFR3 EGFR
8 sarcoma 30.4 TP53 PIK3CA MSH2 FGFR3 FGFR1 BRAF
9 hydrocephalus 30.3 TP53 PTEN FGFR3 FGFR1
10 diffuse astrocytoma 30.2 TP53 MGMT IDH1 H3-3A EGFR BRAF
11 anaplastic astrocytoma 30.2 TP53 PTEN MGMT IDH1 H3-3A EGFR
12 high grade glioma 30.1 TP53 PTEN PIK3CA MGMT EGFR ATM
13 glioma 30.0 TP53 PTEN PIK3CA IDH1 H3-3A FGFR1
14 brain cancer 29.8 TP53 PTEN PIK3R1 PIK3CA MGMT IDH1
15 colorectal cancer 29.1 TP53 PTEN POLE PIK3R1 PIK3CA MSH2
16 gliosarcoma 29.0 TP53 TACC3 TACC1 SEPTIN14 PTEN POLE
17 fgfr craniosynostosis syndromes 10.5 FGFR3 FGFR1
18 nevus of ota 10.5 TP53 BRAF
19 actinic cheilitis 10.5 TP53 MSH2 FGFR3
20 cheilitis 10.5 TP53 MSH2 FGFR3
21 esophagus verrucous carcinoma 10.5 TP53 EGFR
22 acneiform dermatitis 10.4 EGFR BRAF
23 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
24 lip cancer 10.4 TP53 MSH2 BRAF
25 neuroma 10.4 MSH2 MGMT FGFR1
26 adult brain stem glioma 10.4 MGMT IDH1 H3-3A
27 neurofibroma 10.4 TP53 PTEN EGFR
28 acoustic neuroma 10.4 MSH2 MGMT LZTR1
29 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
30 ovarian clear cell adenofibroma 10.4 PTEN PIK3CA
31 spinal cord astrocytoma 10.4 MGMT IDH1 H3-3A
32 thymus lymphoma 10.4 TP53 TACC3
33 temporal lobe neoplasm 10.4 MGMT IDH1
34 spitz nevus 10.4 TP53 BRAF
35 gliofibroma 10.4 TP53 MGMT IDH1
36 bone giant cell sarcoma 10.4 TP53 H3-3A
37 cystadenocarcinoma 10.4 TP53 PIK3CA BRAF
38 adult oligodendroglioma 10.4 IDH1 H3-3A FGFR1
39 childhood pilocytic astrocytoma 10.4 IDH1 H3-3A BRAF
40 skin benign neoplasm 10.4 MSH2 FGFR3 BRAF
41 hereditary mixed polyposis syndrome 10.4 PTEN POLE MSH2
42 anal squamous cell carcinoma 10.4 TP53 PIK3CA MGMT
43 testicular germ cell tumor 10.4 MSH2 FGFR3 BRAF
44 peritoneum cancer 10.4 TP53 PTEN EGFR
45 spinal cancer 10.4 LZTR1 IDH1 H3-3A
46 cervical adenoma malignum 10.4 TP53 MSH2 ATM
47 plagiocephaly 10.4 FGFR3 FGFR1
48 familial colorectal cancer 10.4 TP53 POLE MSH2 BRAF
49 skin papilloma 10.4 TP53 PTEN EGFR
50 vulva squamous cell carcinoma 10.4 TP53 PIK3CA EGFR

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma
Sources

Symptoms & Phenotypes for Giant Cell Glioblastoma

About this section

UMLS symptoms related to Giant Cell Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.93 EGFR PIK3CA
2 Decreased viability GR00055-A-2 9.93 EGFR PIK3CA
3 Decreased viability GR00221-A-1 9.93 EGFR FGFR1 FGFR3 PIK3CA PIK3R1
4 Decreased viability GR00221-A-2 9.93 FGFR1 FGFR3 PIK3CA
5 Decreased viability GR00221-A-3 9.93 FGFR3 PIK3R1
6 Decreased viability GR00221-A-4 9.93 EGFR PIK3CA
7 Decreased viability GR00249-S 9.93 FGFR3
8 Decreased viability GR00386-A-1 9.93 FGFR1
9 Decreased viability GR00402-S-2 9.93 PIK3CA
10 Decreased cell migration GR00055-A-1 9.55 ATM FGFR3
11 Decreased cell migration GR00055-A-3 9.55 BRAF EGFR PIK3CA
12 Reduced mammosphere formation GR00396-S 9.17 ATM BRAF DNMT3A EGFR PIK3R1 POLE

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 ATM BRAF CREBBP DNMT3A EGFR FGFR1
2 hematopoietic system MP:0005397 10.39 ATM BRAF CREBBP DNMT3A EGFR FGFR1
3 growth/size/body region MP:0005378 10.37 ATM BRAF CREBBP DNMT3A EGFR FGFR1
4 homeostasis/metabolism MP:0005376 10.37 ATM BRAF CREBBP DNMT3A EGFR FGFR1
5 mortality/aging MP:0010768 10.33 ATM BRAF CREBBP DNMT3A EGFR FGFR1
6 immune system MP:0005387 10.32 ATM BRAF CREBBP EGFR FGFR1 FGFR3
7 endocrine/exocrine gland MP:0005379 10.31 ATM BRAF CREBBP DNMT3A EGFR FGFR1
8 embryo MP:0005380 10.25 ATM BRAF CREBBP DNMT3A EGFR FGFR1
9 adipose tissue MP:0005375 10.24 ATM BRAF CREBBP DNMT3A EGFR PIK3CA
10 integument MP:0010771 10.23 ATM BRAF CREBBP EGFR FGFR1 FGFR3
11 craniofacial MP:0005382 10.17 BRAF CREBBP EGFR FGFR1 FGFR3 LZTR1
12 digestive/alimentary MP:0005381 10.16 BRAF CREBBP EGFR FGFR1 FGFR3 MSH2
13 neoplasm MP:0002006 10.13 ATM BRAF CREBBP EGFR FGFR3 MGMT
14 muscle MP:0005369 10.07 BRAF CREBBP DNMT3A EGFR FGFR1 LZTR1
15 nervous system MP:0003631 10.07 ATM BRAF CREBBP DNMT3A EGFR FGFR1
16 limbs/digits/tail MP:0005371 10.03 BRAF CREBBP EGFR FGFR1 FGFR3 PTEN
17 normal MP:0002873 9.81 BRAF CREBBP EGFR FGFR1 FGFR3 PIK3R1
18 respiratory system MP:0005388 9.56 BRAF CREBBP EGFR FGFR3 IDH1 MGMT
19 skeleton MP:0005390 9.4 BRAF CREBBP DNMT3A EGFR FGFR1 FGFR3
Sources

Drugs & Therapeutics for Giant Cell Glioblastoma

About this section

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
2
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
3
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
5
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
6
acetic acid Approved Phase 2 64-19-7 176
7
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
8
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
9
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
10
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 5310940 9887054 6857599 43805
13
Aminolevulinic acid Approved Phase 2 106-60-5 137
14
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
15
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
16
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
18
tipifarnib Investigational Phase 2 192185-72-1 159324
19
Motexafin gadolinium Investigational Phase 1, Phase 2 246252-06-2, 156436-89-4 12047567
20
Cediranib Investigational Phase 2 288383-20-0 9933475
21
Maleic acid Experimental Phase 2 110-16-7 444266
22 Gossypol Investigational Phase 2 303-45-7
23 Misonidazole Investigational Phase 2 13551-87-6
24
Trebananib Investigational Phase 2 894356-79-7
25
Fenretinide Investigational Phase 2 65646-68-6
26 Protein Kinase Inhibitors Phase 2
27 Antifungal Agents Phase 2
28 Antibiotics, Antitubercular Phase 2
29 Immunosuppressive Agents Phase 2
30 Anti-Bacterial Agents Phase 2
31 Anti-Infective Agents Phase 2
32 Hormones Phase 2
33 Calcium, Dietary Phase 2
34 calcium channel blockers Phase 2
35 Carboxyamido-triazole Phase 2
36 Arginyl-glycyl-aspartic acid Phase 1, Phase 2
37 Radiopharmaceuticals Phase 1, Phase 2
38 Fluorodeoxyglucose F18 Phase 1, Phase 2
39 Neurotransmitter Agents Phase 1, Phase 2
40 Fluorides Phase 1, Phase 2
41 N-Methylaspartate Phase 1, Phase 2
42 retinol Phase 2
43 Retinol palmitate Phase 2
44 Spermatocidal Agents Phase 2
45
Retinol acetate Phase 2 127-47-9 10245972
46 Contraceptive Agents Phase 2
47 Contraceptive Agents, Male Phase 2
48 Adjuvants, Immunologic Phase 2
49 Gossypol acetic acid Phase 2
50
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
2 Phase II Study of R115777 for the Treatment of Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00058097 Phase 2 tipifarnib
3 A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme Completed NCT00052208 Phase 1, Phase 2 gefitinib
4 Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) Completed NCT00014170 Phase 2 gefitinib
5 Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00004146 Phase 2 carboxyamidotriazole
6 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
7 A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
8 A Phase II Study of AZD2171 in Recurrent Glioblastoma Completed NCT00305656 Phase 2 cediranib maleate
9 Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma Completed NCT00238303 Phase 2 vorinostat
10 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
11 A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
12 A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
13 Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
14 A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme Completed NCT00039494 Phase 2 erlotinib hydrochloride;temozolomide
15 Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy) Completed NCT01753713 Phase 2 dovitinib
16 A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme Completed NCT00445588 Phase 2 erlotinib hydrochloride;sorafenib tosylate
17 A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00085254 Phase 1, Phase 2 cilengitide;temozolomide
18 A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs Completed NCT00662506 Phase 1, Phase 2 Cediranib Maleate;Temozolomide
19 Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme Completed NCT00641706 Phase 2 vorinostat;bortezomib
20 Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI Completed NCT00902577 Phase 2 FMISO
21 A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed NCT01894061 Phase 2
22 A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00980343 Phase 2 vismodegib
23 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
24 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00731731 Phase 1, Phase 2 Temozolomide;Vorinostat
25 Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma Active, not recruiting NCT01149850 Phase 2 temozolomide
26 Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma Active, not recruiting NCT01730950 Phase 2
27 Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma Active, not recruiting NCT01609790 Phase 2
28 Phase II Trial of EMD 121974 for Recurrent Glioblastoma: A Clinical Trial With Tissue Correlates of Response Terminated NCT00112866 Phase 2 cilengitide
29 A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma Terminated NCT01122901 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
30 A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme Terminated NCT00075491 Phase 2 fenretinide
31 Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults With Newly Diagnosed Glioblastoma Multiforme Terminated NCT00005856 Phase 1, Phase 2 oxaliplatin
32 A Phase 2 Comparative Study of 5-Aminolevulinic Acid (5-ALA) and Intraoperative MRI (iMRI) to Enhance Completeness of Resection of Glioblastoma Terminated NCT01575275 Phase 2 aminolevulinic acid
33 A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme Withdrawn NCT03014804 Phase 2
34 A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme Completed NCT00316849 Phase 1 temsirolimus;temozolomide
35 Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma Completed NCT00045565 Phase 1 arsenic trioxide
36 Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00049387 Phase 1 tipifarnib;temozolomide
37 PHASE I TRIAL OF GADOLINIUM TEXAPHYRIN (PCI -0120) AS A RADIOSENSITIZER DURING STEREOTACTIC RADIOSURGERY BOOST FOR GLIOBLASTOMA MULTIFORME Completed NCT00004262 Phase 1 motexafin gadolinium
38 A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma Completed NCT00979862 Phase 1 Cediranib Maleate;Cilengitide
39 Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT02227901 Phase 1 Tipifarnib;Temozolomide
40 Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib Terminated NCT01122888 Phase 1 Cilengitide
41 Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed Glioblastoma Active, not recruiting NCT01957956 Early Phase 1 Temozolomide
42 Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Recurrent Glioblastoma Suspended NCT03360708 Early Phase 1

Search NIH Clinical Center for Giant Cell Glioblastoma

Sources

Genetic Tests for Giant Cell Glioblastoma

About this section
Sources

Anatomical Context for Giant Cell Glioblastoma

About this section

MalaCards organs/tissues related to Giant Cell Glioblastoma:

40
Brain, Eye, Endothelial, Cortex, Cerebellum, Medulla Oblongata
Sources

Publications for Giant Cell Glioblastoma

About this section

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 131)
# Title Authors PMID Year
1
Genetic profile of the giant cell glioblastoma. 61 54
10068201 1999
2
p53 mutations versus EGF receptor expression in giant cell glioblastomas. 54 61
9370234 1997
3
Differentiating Giant Cell Glioblastoma from Classic Glioblastoma With Diffusion-Weighted Imaging. 61
33127573 2021
4
Giant cell glioblastoma in 6-year-old kid: Report of an unusual case. 61
33363854 2020
5
Giant cell glioblastoma multiforme presents as acute pathological nontraumatic subdural haematoma. 61
33369511 2020
6
Characterization and Histological Examination of a Rare Giant Cell Glioblastoma. 61
32821583 2020
7
Update on Circumscribed Gliomas and Glioneuronal Tumors. 61
32389265 2020
8
Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. 61
33392505 2020
9
Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. 61
31655917 2020
10
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. 61
32642724 2020
11
Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 61
30861589 2019
12
Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. 61
31464386 2019
13
Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. 61
31009783 2019
14
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. 61
30368636 2019
15
An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. 61
31394931 2019
16
Subgaleal and brain abscesses due to Salmonella enteritidis following craniotomy for giant cell glioblastoma multiforme: A case report and literature review. 61
31528375 2019
17
Imaging findings in the progression of a giant cell glioblastoma. 61
30128062 2018
18
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30783357 2018
19
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
20
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30443141 2018
21
Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. 61
29805603 2018
22
IDH-mutant giant cell glioblastoma: A neglected tumor variant? 61
29035191 2017
23
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. 61
28288541 2017
24
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. 61
29114311 2017
25
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. 61
28261869 2017
26
Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. 61
28109858 2017
27
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. 61
28161760 2017
28
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. 61
26443480 2016
29
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. 61
27013816 2016
30
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 61
27253461 2016
31
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. 61
26344331 2015
32
Giant cell glioblastoma with calcification and long-term survival. 61
26960525 2015
33
A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. 61
26441479 2015
34
Adult classical glioblastoma with a BRAF V600E mutation. 61
25885250 2015
35
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. 61
25037316 2014
36
Treatment and survival of patients harboring histological variants of glioblastoma. 61
24980627 2014
37
[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. 61
25567590 2014
38
Estimating the surface area of nonconvex particles from central planar sections. 61
24832486 2014
39
Cerebellar giant cell glioblastoma multiforme in an adult. 61
25002780 2014
40
BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. 61
24345274 2014
41
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. 61
23702739 2013
42
Epithelioid GBMs show a high percentage of BRAF V600E mutation. 61
23552385 2013
43
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. 61
22241593 2013
44
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. 61
22943956 2013
45
Giant cell glioblastoma in the pediatric age group: Report of two cases. 61
23772243 2013
46
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. 61
22286149 2012
47
Giant cell glioblastoma in a child: A rare case report. 61
23293671 2012
48
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. 61
21319330 2012
49
Highly malignant behavior of a murine oligodendrocyte precursor cell line following transplantation into the demyelinated and nondemyelinated central nervous system. 61
22420305 2012
50
Glioblastoma multiforme in children: report of 13 cases and review of the literature. 61
21824566 2011
Sources

Variations for Giant Cell Glioblastoma

About this section

ClinVar genetic disease variations for Giant Cell Glioblastoma:

6 (show top 50) (show all 229)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCOR NM_001123385.2(BCOR):c.3881_3882AG[1] (p.Leu1296fs) Microsatellite other 284290 rs886042842 X:39922288-39922289 X:40063035-40063036
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV other 438772 rs1556339256 X:70357729-70357729 X:71137879-71137879
3 H3-3A NM_002107.6(H3-3A):c.103G>A (p.Gly35Arg) SNV other 438766 rs1553260624 1:226252155-226252155 1:226064454-226064454
4 MSH2 NM_000251.2(MSH2):c.1958_1965del (p.Asn653fs) Deletion Pathogenic 590849 rs1558518449 2:47702360-47702367 2:47475221-47475228
5 ATM NM_000051.3(ATM):c.8535G>A (p.Trp2845Ter) SNV Likely pathogenic 555284 rs1555138291 11:108216586-108216586 11:108345859-108345859
6 DNMT3A NM_022552.5(DNMT3A):c.2710C>T (p.Pro904Ser) SNV Likely pathogenic 635110 rs1558650888 2:25457177-25457177 2:25234308-25234308
7 POLE NM_006231.3(POLE):c.1231G>T (p.Val411Leu) SNV Likely pathogenic 376503 rs1057519945 12:133250289-133250289 12:132673703-132673703
8 TP53 NM_000546.5(TP53):c.584T>A (p.Ile195Asn) SNV Likely pathogenic 376618 rs760043106 17:7578265-7578265 17:7674947-7674947
9 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 17:7579313-7579313 17:7675995-7675995
10 TP53 NM_000546.5(TP53):c.332T>C (p.Leu111Pro) SNV Likely pathogenic 376630 rs1057519997 17:7579355-7579355 17:7676037-7676037
11 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
12 TP53 NM_000546.5(TP53):c.730G>C (p.Gly244Arg) SNV Likely pathogenic 376602 rs1057519989 17:7577551-7577551 17:7674233-7674233
13 TP53 NM_000546.6(TP53):c.730G>T SNV Likely pathogenic 376599 rs1057519989 17:7577551-7577551 17:7674233-7674233
14 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
15 TP53 NM_000546.5(TP53):c.614A>C (p.Tyr205Ser) SNV Likely pathogenic 376683 rs1057520007 17:7578235-7578235 17:7674917-7674917
16 TP53 NM_000546.5(TP53):c.796G>C (p.Gly266Arg) SNV Likely pathogenic 376605 rs1057519990 17:7577142-7577142 17:7673824-7673824
17 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
18 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr) SNV Likely pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
19 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr) SNV Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
20 PIK3CA NM_006218.4(PIK3CA):c.1357G>C (p.Glu453Gln) SNV Likely pathogenic 376471 rs1057519925 3:178928079-178928079 3:179210291-179210291
21 FGFR1 NM_023110.2(FGFR1):c.1966A>G (p.Lys656Glu) SNV Likely pathogenic 224897 rs869320694 8:38272308-38272308 8:38414790-38414790
22 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly) SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
23 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser) SNV Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
24 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 17:7577580-7577580 17:7674262-7674262
25 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely pathogenic 376488 rs1057519938 3:178921552-178921552 3:179203764-179203764
26 TP53 NM_000546.5(TP53):c.824G>C (p.Cys275Ser) SNV Likely pathogenic 376583 rs863224451 17:7577114-7577114 17:7673796-7673796
27 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 17:7578394-7578394 17:7675076-7675076
28 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp) SNV Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
29 TP53 NM_000546.5(TP53):c.845G>A (p.Arg282Gln) SNV Likely pathogenic 237956 rs730882008 17:7577093-7577093 17:7673775-7673775
30 TP53 NM_000546.5(TP53):c.584T>G (p.Ile195Ser) SNV Likely pathogenic 376619 rs760043106 17:7578265-7578265 17:7674947-7674947
31 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu) SNV Likely pathogenic 376608 rs1057519991 17:7578394-7578394 17:7675076-7675076
32 TP53 NM_000546.5(TP53):c.647T>G (p.Val216Gly) SNV Likely pathogenic 376671 rs1057520004 17:7578202-7578202 17:7674884-7674884
33 TP53 NM_000546.5(TP53):c.726C>G (p.Cys242Trp) SNV Likely pathogenic 376580 rs375874539 17:7577555-7577555 17:7674237-7674237
34 TP53 NM_000546.5(TP53):c.746G>C (p.Arg249Thr) SNV Likely pathogenic 376015 rs587782329 17:7577535-7577535 17:7674217-7674217
35 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
36 TP53 NM_000546.5(TP53):c.797G>T (p.Gly266Val) SNV Likely pathogenic 233303 rs193920774 17:7577141-7577141 17:7673823-7673823
37 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
38 BRAF NM_004333.6(BRAF):c.1786G>A (p.Gly596Ser) SNV Likely pathogenic 376374 rs121913361 7:140453149-140453149 7:140753349-140753349
39 EGFR NM_005228.5(EGFR):c.866C>T (p.Ala289Val) SNV Likely pathogenic 376209 rs149840192 7:55221822-55221822 7:55154129-55154129
40 MYCNOS NM_005378.6(MYCN):c.131C>T (p.Pro44Leu) SNV Likely pathogenic 376460 rs1057519919 2:16082317-16082317 2:15942195-15942195
41 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val) SNV Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
42 EGFR NM_005228.5(EGFR):c.322A>G (p.Arg108Gly) SNV Likely pathogenic 376400 rs1057519888 7:55211079-55211079 7:55143386-55143386
43 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
44 TP53 NM_000546.5(TP53):c.731G>T (p.Gly244Val) SNV Likely pathogenic 376601 rs985033810 17:7577550-7577550 17:7674232-7674232
45 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 17:7578236-7578236 17:7674918-7674918
46 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 17:7578191-7578191 17:7674873-7674873
47 TP53 NM_000546.5(TP53):c.725G>T (p.Cys242Phe) SNV Likely pathogenic 376578 rs121912655 17:7577556-7577556 17:7674238-7674238
48 EGFR NM_005228.5(EGFR):c.865_866delinsAA (p.Ala289Asn) Indel Likely pathogenic 376397 rs1057519887 7:55221821-55221822 7:55154128-55154129
49 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys) SNV Likely pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
50 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
Sources

Expression for Giant Cell Glioblastoma

About this section
Search GEO for disease gene expression data for Giant Cell Glioblastoma.
Sources

Pathways for Giant Cell Glioblastoma

About this section

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.92 TP53 PTEN PIK3R1 H3-3A FGFR3 FGFR1
2
ERK Signaling 63
Show member pathways
 13.89 TP53 PTEN PIK3R1 H3-3A FGFR3 FGFR1
3
TGF-Beta Pathway 63
Show member pathways
 13.61 TP53 PIK3R1 PIK3CA H3-3A FGFR3 FGFR1
4
Developmental Biology 65
Show member pathways
 13.58 PIK3R1 PIK3CA H3-3A FGFR3 FGFR1 EGFR
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.43 TP53 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
6
GAB1 signalosome 65
Show member pathways
 13.19 TP53 PTEN PIK3R1 PIK3CA FGFR3 FGFR1
7
Phospholipase-C Pathway 63
Show member pathways
 13.14 TP53 PTEN PIK3R1 FGFR3 FGFR1 EGFR
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.13 TP53 PIK3R1 PIK3CA EGFR CREBBP BRAF
9
Human cytomegalovirus infection 36
Show member pathways
 13.02 TP53 PIK3R1 PIK3CA EGFR CREBBP ATM
10
PI3K-Akt signaling pathway 36
Show member pathways
 12.98 TP53 PTEN PIK3R1 PIK3CA FGFR3 FGFR1
11
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.92 PTEN PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
12
MAPK signaling pathway 36 1
12.84 TP53 FGFR3 FGFR1 EGFR BRAF
13
Gastric cancer 36
Show member pathways
 12.83 TP53 PTEN PIK3R1 PIK3CA FGFR1 EGFR
14
Ras signaling pathway 36
Show member pathways
 12.81 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
15
Endometrial cancer 36
Show member pathways
 12.8 TP53 PTEN PIK3R1 PIK3CA MSH2 FGFR1
16
Development HGF signaling pathway 23
Show member pathways
 12.79 TP53 PTEN PIK3R1 PIK3CA BRAF
17
Chks in Checkpoint Regulation 63
Show member pathways
 12.78 TP53 POLE MSH2 MGMT ATM
18
NF-KappaB Family Pathway 63
Show member pathways
 12.78 PIK3R1 FGFR3 FGFR1 EGFR CREBBP
19
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.78 TP53 PTEN PIK3R1 PIK3CA FGFR3 FGFR1
20
4-1BB Pathway 63
Show member pathways
 12.74 TP53 PIK3R1 EGFR CREBBP BRAF
21
Regulation of actin cytoskeleton 36 1
12.71 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
22
Glioma 36
Show member pathways
 12.68 TP53 PTEN PIK3R1 PIK3CA FGFR1 EGFR
23
Immune response IL-23 signaling pathway 23
Show member pathways
 12.66 TP53 PIK3R1 PIK3CA MSH2 EGFR
24
Negative regulation of FGFR1 signaling 65
Show member pathways
 12.65 PIK3R1 PIK3CA FGFR3 FGFR1 BRAF
25
DNA Damage 4
12.59 TP53 TACC3 MSH2 MGMT ATM
26
VEGF Signaling 66
Show member pathways
 12.59 TP53 PTEN PIK3CA FGFR3 FGFR1 EGFR
27
ErbB signaling pathway 36 1
Show member pathways
 12.59 TP53 PTEN PIK3R1 PIK3CA FGFR3 EGFR
28
Pathways in cancer 36
12.58 TP53 PTEN PIK3R1 PIK3CA MSH2 FGFR3
29
Chromatin Regulation / Acetylation 4
12.49 MGMT H3-3A DNMT3A CREBBP
30
mTOR signalling 65
Show member pathways
 12.48 PIK3R1 PIK3CA FGFR3 FGFR1
31
JAK-STAT signaling pathway 36
Show member pathways
 12.48 PIK3R1 PIK3CA EGFR CREBBP
32
Development FGFR signaling pathway 23
Show member pathways
 12.48 PIK3R1 PIK3CA FGFR3 FGFR1
33
Apoptosis Pathway 70
Show member pathways
 12.48 TP53 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
34
RhoGDI Pathway 63
Show member pathways
 12.47 PIK3R1 FGFR3 FGFR1 EGFR
35
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.47 PTEN PIK3R1 PIK3CA BRAF
36
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.47 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
37
Shigellosis 36
12.47 TP53 PIK3R1 PIK3CA H3-3A EGFR ATM
38
Development IGF-1 receptor signaling 23
Show member pathways
 12.46 TP53 PTEN PIK3R1 PIK3CA
39
DNA Damage/Telomere Stress Induced Senescence 65
Show member pathways
 12.43 TP53 H3-3A CREBBP ATM
40
Development ERBB-family signaling 23
Show member pathways
 12.42 PIK3R1 PIK3CA EGFR BRAF
41
cAMP signaling pathway 36
12.41 PIK3R1 PIK3CA CREBBP BRAF
42
Human T-cell leukemia virus 1 infection 36
12.41 TP53 PTEN PIK3R1 PIK3CA CREBBP ATM
43
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.4 PIK3R1 PIK3CA EGFR CREBBP
44
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.39 TP53 PTEN PIK3R1 PIK3CA EGFR
45
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.39 TP53 PTEN PIK3R1 PIK3CA FGFR3 FGFR1
46
Toll Comparative Pathway 63
Show member pathways
 12.38 TP53 PIK3R1 PIK3CA FGFR1
47
Viral carcinogenesis 36
12.38 TP53 PIK3R1 PIK3CA CREBBP
48
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.38 TP53 PIK3R1 EGFR BRAF
49
Proteoglycans in cancer 36
12.37 TP53 PIK3R1 PIK3CA FGFR1 EGFR BRAF
50
Signaling by FGFR2 65
Show member pathways
 12.35 PIK3R1 PIK3CA FGFR3 FGFR1 BRAF
Sources

GO Terms for Giant Cell Glioblastoma

About this section

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.03 TP53 TACC3 TACC1 SEPTIN14 PTEN PIK3R1
2 nucleus GO:0005634 9.83 TP53 TACC1 PTEN POLE PIK3R1 MSH2
3 phosphatidylinositol 3-kinase complex, class IA GO:0005943 8.62 PIK3R1 PIK3CA

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 10 TP53 POLE MSH2 MGMT ATM
2 phosphorylation GO:0016310 9.99 PIK3CA FGFR3 FGFR1 EGFR BRAF ATM
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 PTEN FGFR3 EGFR BRAF
4 negative regulation of apoptotic process GO:0043066 9.85 TP53 PTEN PIK3R1 MGMT EGFR BRAF
5 protein autophosphorylation GO:0046777 9.8 FGFR3 FGFR1 EGFR ATM
6 multicellular organism growth GO:0035264 9.77 TP53 H3-3A ATM
7 phosphatidylinositol biosynthetic process GO:0006661 9.77 PTEN PIK3R1 PIK3CA
8 positive regulation of kinase activity GO:0033674 9.76 FGFR3 FGFR1 EGFR
9 cellular response to drug GO:0035690 9.73 TP53 EGFR BRAF
10 peptidyl-tyrosine phosphorylation GO:0018108 9.73 FGFR3 FGFR1 EGFR BRAF
11 phosphatidylinositol-mediated signaling GO:0048015 9.71 PIK3R1 PIK3CA FGFR1
12 response to organic cyclic compound GO:0014070 9.71 PTEN MGMT IDH1 EGFR
13 cellular response to UV GO:0034644 9.7 TP53 PIK3R1 CREBBP
14 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.65 PIK3R1 MSH2 ATM
15 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PTEN PIK3R1 PIK3CA
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 TP53 EGFR
17 positive regulation of phospholipase activity GO:0010518 9.58 FGFR3 FGFR1
18 regulation of axon regeneration GO:0048679 9.55 PTEN BRAF
19 positive regulation of protein kinase B signaling GO:0051897 9.55 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
20 ERBB2 signaling pathway GO:0038128 9.5 PIK3R1 PIK3CA EGFR
21 protein phosphorylation GO:0006468 9.5 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
22 determination of adult lifespan GO:0008340 9.43 TP53 MSH2 ATM
23 epidermal growth factor receptor signaling pathway GO:0007173 8.92 PIK3R1 PIK3CA EGFR BRAF

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.51 TP53 TACC3 TACC1 SEPTIN14 PTEN POLE
2 ATP binding GO:0005524 10.03 TP53 PIK3CA MSH2 FGFR3 FGFR1 EGFR
3 nucleotide binding GO:0000166 9.97 SEPTIN14 POLE PIK3CA MSH2 FGFR3 FGFR1
4 kinase activity GO:0016301 9.93 PIK3CA FGFR3 FGFR1 EGFR BRAF ATM
5 protein kinase activity GO:0004672 9.92 FGFR3 FGFR1 EGFR BRAF ATM
6 identical protein binding GO:0042802 9.81 TP53 PTEN IDH1 FGFR3 FGFR1 EGFR
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 FGFR3 FGFR1 EGFR
8 protein tyrosine kinase activity GO:0004713 9.56 FGFR3 FGFR1 EGFR BRAF
9 insulin receptor substrate binding GO:0043560 9.51 PIK3R1 PIK3CA
10 1-phosphatidylinositol-3-kinase activity GO:0016303 9.49 PIK3CA ATM
11 chromatin binding GO:0003682 9.43 TP53 POLE MSH2 EGFR DNMT3A CREBBP
12 fibroblast growth factor-activated receptor activity GO:0005007 9.4 FGFR3 FGFR1
13 DNA-methyltransferase activity GO:0009008 9.37 MGMT DNMT3A
14 transferase activity GO:0016740 9.32 POLE PIK3CA MGMT FGFR3 FGFR1 EGFR
Sources

Sources for Giant Cell Glioblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....